Free Trial

Zymeworks (ZYME) Competitors

Zymeworks logo
$13.33 -0.68 (-4.85%)
Closing price 04:00 PM Eastern
Extended Trading
$13.28 -0.05 (-0.38%)
As of 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ZYME vs. SRRK, ACAD, VKTX, SWTX, PTGX, MLTX, IMVT, AAPG, CRNX, and KYMR

Should you be buying Zymeworks stock or one of its competitors? The main competitors of Zymeworks include Scholar Rock (SRRK), ACADIA Pharmaceuticals (ACAD), Viking Therapeutics (VKTX), SpringWorks Therapeutics (SWTX), Protagonist Therapeutics (PTGX), MoonLake Immunotherapeutics (MLTX), Immunovant (IMVT), Ascentage Pharma Group International (AAPG), Crinetics Pharmaceuticals (CRNX), and Kymera Therapeutics (KYMR). These companies are all part of the "pharmaceutical products" industry.

Zymeworks vs. Its Competitors

Zymeworks (NYSE:ZYME) and Scholar Rock (NASDAQ:SRRK) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and risk.

Scholar Rock has a net margin of 0.00% compared to Zymeworks' net margin of -182.75%. Zymeworks' return on equity of -23.00% beat Scholar Rock's return on equity.

Company Net Margins Return on Equity Return on Assets
Zymeworks-182.75% -23.00% -18.04%
Scholar Rock N/A -118.22%-82.01%

Zymeworks has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Zymeworks, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zymeworks$93.38M9.95-$118.67M-$1.49-8.95
Scholar Rock$33.19M111.43-$246.29M-$2.53-15.40

Zymeworks currently has a consensus price target of $21.00, suggesting a potential upside of 57.54%. Scholar Rock has a consensus price target of $42.67, suggesting a potential upside of 9.54%. Given Zymeworks' higher probable upside, equities analysts clearly believe Zymeworks is more favorable than Scholar Rock.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zymeworks
0 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.90
Scholar Rock
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
3.13

In the previous week, Scholar Rock had 10 more articles in the media than Zymeworks. MarketBeat recorded 11 mentions for Scholar Rock and 1 mentions for Zymeworks. Scholar Rock's average media sentiment score of 0.92 beat Zymeworks' score of 0.33 indicating that Scholar Rock is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Zymeworks
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Scholar Rock
5 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Zymeworks has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Comparatively, Scholar Rock has a beta of 0.33, meaning that its share price is 67% less volatile than the S&P 500.

92.9% of Zymeworks shares are held by institutional investors. Comparatively, 91.1% of Scholar Rock shares are held by institutional investors. 1.9% of Zymeworks shares are held by company insiders. Comparatively, 13.3% of Scholar Rock shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Zymeworks beats Scholar Rock on 9 of the 15 factors compared between the two stocks.

Get Zymeworks News Delivered to You Automatically

Sign up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZYME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ZYME vs. The Competition

MetricZymeworksPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$928.87M$776.90M$5.70B$21.12B
Dividend YieldN/A4.84%4.69%3.60%
P/E Ratio-8.891.4028.0728.44
Price / Sales9.9525.35449.2060.36
Price / CashN/A19.5636.2222.92
Price / Book2.016.798.664.69
Net Income-$118.67M-$4.32M$3.25B$995.51M
7 Day Performance-6.46%1.33%4.20%1.64%
1 Month Performance4.88%3.74%10.82%5.92%
1 Year Performance25.40%8.18%34.70%11.50%

Zymeworks Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ZYME
Zymeworks
2.8989 of 5 stars
$13.33
-4.9%
$21.00
+57.5%
+34.7%$928.87M$93.38M-8.89460Upcoming Earnings
SRRK
Scholar Rock
3.2631 of 5 stars
$38.59
+3.1%
$42.67
+10.6%
+342.4%$3.66B$33.19M-15.25140
ACAD
ACADIA Pharmaceuticals
4.2594 of 5 stars
$21.89
+4.3%
$27.88
+27.3%
+24.7%$3.66B$957.80M15.98510Positive News
Analyst Forecast
VKTX
Viking Therapeutics
4.8493 of 5 stars
$31.63
+1.7%
$87.15
+175.5%
-33.5%$3.55BN/A-27.5020Trending News
Earnings Report
Analyst Forecast
Analyst Revision
SWTX
SpringWorks Therapeutics
1.3425 of 5 stars
$46.99
flat
$52.57
+11.9%
N/A$3.54B$191.59M-13.78230
PTGX
Protagonist Therapeutics
1.3781 of 5 stars
$55.23
+4.2%
$66.10
+19.7%
+28.3%$3.42B$434.43M73.64120News Coverage
Insider Trade
MLTX
MoonLake Immunotherapeutics
2.1674 of 5 stars
$50.86
+3.8%
$74.50
+46.5%
+20.7%$3.26BN/A-22.112News Coverage
Positive News
Options Volume
IMVT
Immunovant
1.6052 of 5 stars
$18.59
+2.5%
$36.30
+95.3%
-34.4%$3.18BN/A-6.78120News Coverage
Positive News
Gap Down
AAPG
Ascentage Pharma Group International
N/A$36.20
-5.3%
N/AN/A$3.15B$134.35M0.00600Lockup Expiration
Gap Down
CRNX
Crinetics Pharmaceuticals
3.6692 of 5 stars
$33.02
+3.4%
$69.50
+110.5%
-43.1%$3.09B$1.04M-8.64210Positive News
KYMR
Kymera Therapeutics
3.0325 of 5 stars
$44.90
+0.9%
$59.11
+31.7%
+6.9%$2.92B$47.07M-14.48170Positive News

Related Companies and Tools


This page (NYSE:ZYME) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners